- Home
- JRVR vs INBX Comparison
JRVR vs INBX Comparison
Compare JRVR & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRVR | INBX |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 1.5B |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | JRVR | INBX |
|---|---|---|
| Price | $3.46 | $98.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.72 | ★ $266.67 |
| AVG Volume (30 Days) | 253.2K | ★ 282.4K |
| Earning Date | 11-02-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ 125.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $687,614,000.00 | $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $3.37 | $28.16 |
| 52 Week High | $7.20 | $155.29 |
Technical Indicators
Market Signals| Indicator | JRVR | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 25.65 | 43.08 |
| Support Level | N/A | $96.60 |
| Resistance Level | $4.26 | $106.40 |
| Average True Range (ATR) | 0.11 | 5.75 |
| MACD | -0.02 | -1.44 |
| Stochastic Oscillator | 8.57 | 11.13 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.